March 2019 Issue Table Of Contents

From The Editor

• Is It Time We Stamp Out The Stigma Associated With Depression?

Feature Articles

• John Leonard’s Latest Adventure — Readying Intellia Therapeutics For The Long Haul
• Industry Explorers Blaze On: Howard Fillit
• Companies-To-Watch 2018 Annual Roundup

Capitol Perspectives

• Congress Scrutinizes Rx Pricing As Administration Releases Proposal To Ban Rebates

CEO Corner

• Realizing Aspirations Through Entrepreneurship

From Principles and Policy to Execution

• The Overdue Healthcare Overhaul: Will An Evolution Or Revolution Better Serve Patients?

Companies To Watch

• Azitra

Industry Research

• What Goes Into A CRA Salary?

Inside The Industry

• The Sangamo And TxCell Story: How Two Companies Built A Deal
• Doug Given: From Pharma To Redefining Healthcare
• Paving The Way For Future Funding
• IO Building A New Future For Cancer Treatment
• How Pharma Manufacturers Should Address VRS
• The Microbiome: Unlocking The Mystery Of The “Gut”

Industry Leader

• AI In Life Sciences — Seeing Past The Hype

Leadership Lessons

• 4 Steps to Leading Well in Times of Stress

Ask The Board

• Regarding Clinical Trial Matching Services, How Mature Is This Technology? What Should I Be Looking For If I Want To Use These Services, And Do They Work Well In All Therapeutic Areas?
• Are You Seeing Any Initiatives By The Industry To Adopt The “Public” Blockchain For This And/Or Similar Purposes?
• How Will IT Applications Used In R&D And Manufacturing Change To Meet The New Requirements Associated With Gene Therapy? What New Functionality Will Need To Be Provided?